Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults

What is it about?

Opioid addiction is a devastating disease to many and long-term buprenorphine treatment engagement is associated with better survival and other outcomes. We found that in a commercial insurance population, only less than half of the patients were still engaged in buprenorphine treatment 1 year after initiation. The loss of insurance coverage appeared to be the most significant predictor of disengagement. Receipt of psychotherapy in the first year was associated with better treatment retention.

Featured Image